ABSTRACT The original findings of peripheral anergy in sarcoidosis led to the conclusion that sarcoidosis was a disease associated with immune deficiency, but patients with sarcoidosis do not appear to suffer from repeated infections suggestive of immune suppression. With the technique of bronchoalveolar lavage it is now possible to examine the local immune response within the lung, the most commonly affected organ in sarcoidosis. In this study three different indices of cell mediated immunity (lymphocyte transformation, interleukin-2 production, and interleukin-1 production) have been examined by comparison of cells recovered by lavage with those collected from peripheral blood. It was found that in vitro anergy was confined to peripheral blood cells, where all three markers of the immune response used in this study was impaired in the 12 patients with sarcoidosis group when compared with results in the 12 controls, with the most depressed responses seen in those patients classified as having active disease (lymphocyte proliferation 45% (SD 17%); interleukin-2 production 44% (13%), and interleukin-I production 31% (10%) of control levels). By contrast, T lymphocytes recovered from the lungs of patients with sarcoidosis showed a greater response than did those from controls in terms of lymphocyte transformation and interleukin-2 production; these differences were greatest in those with active disease (lymphocyte proliferation 209% (27%) and interleukin-2 production 202% (19%) of control levels). Interleukin-l production by cells of the monocyte lineage recovered from the lung gave similar results to those of the control and sarcoid groups. It is concluded that the anergy seen in the peripheral blood compartment possibly reflects redistribution of T lymphocytes rather than a generalised immune deficiency.
Introduction
Sarcoidosis is a multisystem disease of unknown cause characterised by non-caseating granuloma formation. It is associated with anergic responses to skln tests and depressed peripheral T lymphocyte responses in vitro.' 2 We have previously shown that this peripheral anergy is partly due to decreased production of the monokine interleukin-I (IL-I) by monocytes. 20 pg/ml) dose of concanavalin A (2,ug/ml:20,u1 of 20,pg/ml solution) was added to three wells, with another three wells acting as control. The plates were then incubated for three days in 5% carbon dioxide in air at 37°C. Eighteen hours before the termination of this culture period 04 pCi of tritiated thymidine was added to each well. Cells were harvested on to glass fibre discs with a Titertek harvester. The discs were then dried and incorporation of tritiated thymidine into cells was determined by liquid scintillation counting using a Tri-Carb 4000 series counter (Packard Instruments Co Inc, USA).
GENERATION OF INTERLEUKIN-1 AND INTERLEUKIN-2
One ml RPMI 1640 containing 5% fetal calf serum was added to the costar plate containing the adherent cells. These adherent cells were then stimulated with 5,pg/ml (100 pl of a 50pg/ml solution) lipopolysaccharide to generate IL-1. A second well remained lipopolysaccharide free and acted as a control. The plates were incubated for 24 hours in an atmosphere of 5% carbon dioxide in air at 37°C and the supernatants were collected, centrifuged, and dialysed against 100 ml RPMI 1640, which was changed five times during 48 hours. The dialysates were stored at -20°C until they were assayed.
We stimulated 2 x 106 non-adherent cells/ml from lavage fluid or peripheral blood with 10 g/ml concanavalin A Sigma UK Ltd (100,l of a lOOpg/ml solution) for 24 hours at 37°C in 5% carbon dioxide in air. After this time concanavalin A was added to control cultures, after which the mitogen was 252 absorbed out of all cultures with Sephadex 100 beads. The samples were then stored at -20°C until they were assayed.
Assays for interleukin-J and interleukin-2 activity
Samples of 100 p1 containing 4 x 106 cells/ml adherent cell depleted mouse thymocytes in RPMI + 5% fetal calf serum were plated into flat bottomed microtitre plates. Fifty millilitres of IL-I containing control supernatant or RPMI was added and then half of the wells were stimulated with phytohaemagglutinin at a final concentration of 0 01 mitogenic units/ml. The plates were then incubated and harvested under the same conditions as for lymphocyte transformation Phytohaemagglutinin stimulated cell lines from peripheral blood were used as the target, the method of Paganelli etal being used. The proliferative response to concanavalin A of lymphocytes recovered by bronchoalveolar lavage from both patients and controls was much less that of lymphocytes from the peripheral blood of controls (figure). The response of cells from peripheral blood to concanavalin A was lower in all patients with sarcoidosis than in controls (p < 0-005). This peripheral anergy was similar in patients with both active and inactive sarcoidosis. In lavage fluid by contrast the patients with sarcoidosis showed a greater proliferative response than did the controls. Subjects with active disease showed a greater response than the inactive group (p < 0-05). There was also spontaneous proliferation in the background unstimulated cultures of lavage lymphocytes from patients with active sarcoidosis (p < 0 05). In terms of the stimulation index the results are similar in the three groups: control 3 3, inactive sarcoidosis 3-1, and active sarcoidosis 2-6.
INTERLEUKIN-2 AND INTERLEUKIN-1 PRODUCTION
The mitogen induced production of IL-2 by peripheral blood lymphocytes was reduced in patients with sarcoidosis, this effect being greatest in the active group (p < 0.01). In fluid both spontaneous production and mitogen induced IL-2 production was increased, greater amounts being produced by the patients with active sarcoidosis than by either of the other two groups. (spontaneous: p < 0-005; stimulated: p < 0 01)
The in vitro peripheral blood anergy associated with sarcoidosis is reflected in the reduced IL-I production, from blood monocytes from the group with sarcoidosis, which was less than 25% of that of the control level (inactive group: p < 0-01; active group: p < 0-005). Production of IL-1 from lavage macrophages was similar in patients with sarcoidosis and in control patients.
Discussion
We have found that the peripheral blood anergy seen in sarcoidosis is reflected by a reduction in the concentrations of IL-1 and IL-2 produced by peripheral T cellfunction, as measured by lymphocyte transformation, interleukin-2 production, and production ofthe monokine interleukin-1, measured in cells recoveredfrom peripheral blood and bronchoalveolar lavagefluid. Bgd-background; LPS-lipopolysaccharide; Con A-concanavalin A; cpm-counts per minute. *-p < 005; **-p < 0 01; *** p < 0001.
blood mononuclear cells. In the lung, however, the increased proliferation of bronchoalveolar lavage fluid lymphocytes observed in both unstimulated and stimulated cultures in patients with active sarcoidosis is probably due to increased production of IL-2 and appears to be independent of IL-1 as no increase in the production of this monokine was observed in cultures of lavage fluid cells. Possibly these observed differences may be due to the smoking habits of the control group (all patients with sarcoidosis were nonsmokers). We found no difference, however, between the smoking and non-smoking controls in any of the indices measured in this study. We have previously shown that the peripheral blood anergy is due to activated cells of the monocyte-macrophage series, which not only have a reduced capacity for IL-I production but also release increased amounts of prostaglandin E2.3 The peripheral blood compartment has also been shown to contain increased proportions of lymphocytes bearing the suppressor phenotype and decreased numbers of T lymphocytes of the helper phenotype.47
In the lung, however, at the site of granuloma formation there is an increase of T lymphocytes, mainly with the helper cell phenotype.7 The question of the origin of these cells arises; do they migrate to the site of presumed immunological insult, thus causing the observed peripheral cell picture by a depletion phenomenon, or is there a local proliferation of helper T cells at the site of granuloma formation after the migration of a subpopulation of activated lymphocytes?
Although we found some spontaneous lymphocyte proliferation in the lavage cells from patients with active sarcoidosis we have also found that mitogen could enhance both proliferation, as measured by tritiated thymidine incorporation, and IL-2 production. This shows that many of the lymphocytes have not been activated in vivo but retain the capacity to be activated when stimulated by an appropriate signal. Possibly therefore they have migrated to the lung, perhaps under the control of a chemotactic factor.14 Other work has suggested that most of the lymphocytes found in lavage fluid from patients with sarcoidosis have arisen as a result of spontaneous local proliferation9 and that this is the source of the increased numbers of T lymphocytes of the helper phenotype. One Our results show that so far as the lung is concerned sarcoidosis is not a disease characterised by cellular immunodeficiency, as has been suggested by earlier work using peripheral blood.'2 Sarcoidosis should be seen as a disorder in which compartmentalisation of the cells of the immune system appears to occur. The stimulus for the proposed celluHudspith, Flint, Geraint-James, Brostoff, Johnson lar migration into granulomas is not known, although T cell derived chemotactic factors have been shown to be produced by lung cells. " These factors could cause traffic of cells from the peripheral blood to the site of granuloma formation, leading to peripheral lymphopenia. The anergy observed in the peripheral compartment could be explained by a combination of this lymphopenia and the effect of chemotactic factors on monocytes that become activated. This leads to increased prostaglandin production and reduced capacity to produce IL-1, thus contributing to the peripheral anergy. What stimulates or controls the observed local cellular proliferation remains unclear.
Our results show that patients with sarcoidosis are not immunologically compromised because there is an activated competent cellular immune response at the site of disease activity, which might be the site of antigen challenge.
